Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702588 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
The incidence of RM-ESRD is increasing, possibly owing to the increased rate of renal cell carcinoma treatment. Although overall survival for RM-ESRD was worse than either that of nonmalignant surgical loss or other known causes, non-cancer-specific mortality was decreased compared to diabetic causes, likely due to systemic effects by cause of ESRD.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Kevin A. M.S., Srinivas M.D., Jamil S. B.S., Randy M.D., Ph.D., Steven C. M.D., Ph.D., Brian M.D.,